In conclusion, this study demonstrates that molecular subtyping may be used as guidance in the selection of a neoadjuvant approach when chemotherapy is indicated for patients with ER-positive and HER2-negative breast cancers. This evidence concerns the gene ERBB2 and breast cancer.